| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 160,45 | 162,05 | 07:43 | |
| 160,45 | 162,05 | 07:43 |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 285,00 | 10 | |||
| 266,00 | 40 | |||
| 244,00 | 35 | |||
| 222,00 | 50 | |||
| 190,00 | 30 | |||
| 161,30 | 37 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/idp.htm [/URL] | ||||
| 37 | 160,75 | |||
| 40 | 1,234 | |||
| 1.063 | 0,000 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 1.140 | 0,177 | 202 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
| 16:32:04 | 161,35 | 1 |
| 15:58:28 | 160,00 | 94 |
| 15:58:28 | 160,00 | 6 |
| 15:42:24 | 158,55 | 1 |
| 15:37:04 | 158,70 | 9 |
| 15:37:04 | 158,70 | 16 |
| 15:30:04 | 157,85 | 1 |
| 14:56:09 | 158,40 | 44 |
| 14:56:09 | 158,45 | 25 |
| 13:43:29 | 159,00 | 125 |
| 13:34:26 | 158,80 | 10 |
| 12:57:21 | 158,80 | 1 |
| 12:19:34 | 158,80 | 15 |
| 12:13:58 | 158,80 | 11 |
| 11:11:05 | 157,60 | 20 |
| 10:23:29 | 156,50 | 1 |
| 09:04:34 | 155,00 | 2 |
| 09:04:34 | 159,00 | 50 |
| 09:04:34 | 159,00 | 1 |
| Tagesumsatz Xetra | - | 0 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Biogen Inc.: Biogen Announces Board Chair Transition | 499 | GlobeNewswire (Europe) | Caroline Dorsa to retire from the Biogen Board of Directors; Dr. Maria C. Freire, Director since 2021, elected as new ChairCAMBRIDGE, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB)... ► Artikel lesen | |
| Mo | Biogen Posts Q4 Beat, Analysts Raise Price Targets On 'Significant Pipeline Diversification' | 9 | Benzinga.com | ||
| Mo | Spinraza-Potenzial: BMO Capital hebt Biogen-Kursziel auf 196 US-Dollar an | 7 | Investing.com Deutsch | ||
| Mo | BMO Capital raises Biogen stock price target to $196 on Spinraza potential | 5 | Investing.com | ||
| BIOGEN Aktie jetzt für 0€ handeln | |||||
| Mo | Goldman Sachs reiterates Buy rating on Biogen stock amid Leqembi growth | 3 | Investing.com |
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| Mi | Bio-Techne Corporation: Bio-Techne Announces Changes to its Leadership Team | PR Newswire | Dr. Matt McManus to transition from his role as President, Diagnostics and Spatial Biology Segment, effective March 1, 2026
Steve Crouse, Senior Vice President... ► Artikel lesen | |
| Mi | Outlook Therapeutics, Inc.: Outlook Therapeutics Submits Type A Meeting Request to FDA Following Complete Response Letter | GlobeNewswire (Europe) | ISELIN, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of... ► Artikel lesen | |
| Mi | OKYO Pharma Announces Transition of At-The-Market Equity Offering Facility to Leerink Partners | GlobeNewswire (Europe) | LONDON and NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| Mi | FDA lässt Modernas Grippeimpfstoff abblitzen - Aktie fällt zweistellig | BÖRSE ONLINE | Rückschlag für Moderna: Die US-Arzneimittelbehörde verweigert die Prüfung eines neuen mRNA-Grippeimpfstoffs. Noch ist unklar, was das für die Pipeline bedeutet. Die Aktie des BioNTech-Konkurrenten bricht... ► Artikel lesen | |
| Mi | Burcon NutraScience Corporation: Burcon Announces Fiscal 2026 Third Quarter Results | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - February 11, 2026) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in plant-based... ► Artikel lesen |